Japanese Healthtech Stock News

Kioxia Holdings recently reported past third-quarter results showing higher sales and earnings per share year-on-year, and issued fourth-quarter and full-year 2026 guidance that points to significantly higher revenue and operating profit ranges of about ¥845.0 billion to ¥935.0 billion for the quarter and ¥2.18 billion to ¥2.27 billion for the year. The company directly linked its stronger outlook to surging demand and firmer pricing for NAND memory used in data centers and AI servers,...

Why Kao (TSE:4452) is back on investors' radar Kao (TSE:4452) has drawn fresh attention after a packed February 5 update that combined full year 2025 results, new 2026 guidance, a planned share split with higher authorized share capital, and updated dividend plans. See our latest analysis for Kao. At a share price of ¥6,760, Kao has seen a 7.87% 1 month share price return and an 8.07% year to date share price return. Its 3 year total shareholder return of 43.33% suggests momentum has been...

Kuroda Group (TSE:287A) has put up a mixed set of Q3 2026 numbers, with Q2 revenue at ¥30.4b and basic EPS of ¥24.73, alongside trailing twelve month EPS growth of 29.1% even as revenue eased 2.9% and net profit margin moved from 1.7% to 2.3%. Over recent quarters the company has seen quarterly revenue range from ¥29.6b to ¥31.3b and basic EPS move between ¥10.39 and ¥27.61, while trailing twelve month EPS shifted from ¥55.77 to ¥65.39 as total revenue moved from ¥139.3b to ¥120.4b. For...

Why Oji Holdings Stock Is Back in Focus After Its Latest Earnings Oji Holdings (TSE:3861) is back on radar after reporting results for the nine months to December 31, 2025, with sales slightly higher but net income and earnings per share lower year on year. See our latest analysis for Oji Holdings. That earnings update has arrived alongside a clear rebound in sentiment, with a 26.0% 90 day share price return and a 67.84% 1 year total shareholder return suggesting that momentum has been...

m-up holdings (TSE:3661) has just put out its Q3 2026 scorecard, with recent quarterly figures showing revenue moving from ¥6.8b in Q4 2025 to ¥7.4b in Q1 2026 and ¥7.7b in Q2 2026, alongside basic EPS of ¥12.07 and ¥11.84 in Q1 and Q2 respectively and trailing 12 month earnings growth of 66.4%. Over the past few reported periods, revenue has shifted from ¥6.7b in Q3 2025 to ¥7.7b in Q2 2026, while basic EPS has moved from ¥11.48 to ¥11.84 over the same quarters. This gives investors a clear...

Nakano (TSE:1827) has just posted its Q3 2026 numbers, with the latest available quarter showing revenue of ¥31.7 billion and EPS of ¥43.48, backed by net income of ¥1,494 million. The company has seen revenue move from ¥27.9 billion in Q3 2025 to ¥31.7 billion in Q2 2026, while EPS shifted from ¥31.78 to ¥43.48 over the same periods, giving investors a clear view of how the top and bottom lines are tracking into this year. With a trailing net profit margin of 2.8% compared to 3.4% last year,...

Tess Holdings Ltd (TSE:5074) has put another uneven stretch on the board, with Q1 2026 revenue at ¥12.7 billion and basic EPS of ¥0.35, set against a trailing twelve month basic EPS loss of ¥6.45. The company has seen revenue move from ¥7.8 billion in Q4 2024 to ¥8.3 billion in Q1 2025 and then to ¥9.9 billion in Q4 2025 before reaching ¥12.7 billion in Q1 2026. Quarterly EPS has swung between a loss of ¥17.21 and a gain of ¥9.70, leaving investors focused on how quickly margins can stabilise...

In February 2026, Ibiden Co., Ltd. approved a roughly ¥500 billion, three-year capital investment plan to expand production of high-performance IC package substrates for AI and high-performance servers, while also reporting higher nine-month sales and net income and guiding to a lower year-end dividend. The scale of this multiyear capacity build-out, focused on AI-related server demand, marks a significant shift in how Ibiden is positioning its electronics business for its 2030 goals. Next,...

Latest Earnings Snapshot and What Stood Out Nireco (TSE:6863) has reported its Q3 2026 numbers with recent quarterly revenue sitting at ¥2,768 million and Basic EPS at ¥53.54, setting a clear benchmark for how the rest of the year is shaping up. The company has seen revenue move from ¥2,519 million in Q2 2025 to ¥2,662 million in Q3 2025 and then to ¥2,768 million in Q2 2026, while Basic EPS shifted from ¥46.47 to ¥62.45 and then to ¥53.54 over the same quarters, giving you a sense of how the...

Iseki (TSE:6310) has just posted its FY 2025 numbers, with third quarter revenue at ¥42,844 million and basic EPS of ¥37.56. Trailing twelve month figures show revenue of ¥183,558 million and basic EPS of ¥72.09 as the business continues to build on its recent return to profitability. Over recent periods, the company has seen revenue move from ¥168,425 million to ¥183,558 million on a trailing basis, with EPS shifting from a loss of ¥133.59 to a profit of ¥72.09, giving investors a clearer...

GreensLtd (TSE:6547) sets the stage with recent earnings GreensLtd (TSE:6547) has followed up its recent results with a trailing twelve month snapshot that shows total revenue of ¥51.2b and basic EPS of ¥369.15, against year-on-year earnings growth of 8.7% and revenue growth of 5.5%. Over the past reported periods, revenue has moved from ¥10.4b in Q4 2024 to ¥11.0b in Q3 2025 and then ¥13.5b in Q1 2026. Quarterly basic EPS shifted from ¥32.16 to ¥20.77, then to ¥71.60 and ¥113.48 across the...

If you are trying to figure out whether DIC is still reasonably priced or already reflecting a lot of optimism, you will want to look closely at what its current valuation is really telling you. The share price sits at ¥4,250, with returns of 7.1% over the last week, 12.8% over the last month, 17.1% year to date, 35.4% over 1 year, 101.6% over 3 years and 83.4% over 5 years. This puts recent and longer term moves front and center in any assessment of risk and reward. Recent news around DIC...

Loadstar Capital K.K (TSE:3482) has laid out its FY 2025 scorecard with third quarter revenue of ¥8.1b and basic EPS of ¥45.00. This is set against a trailing twelve month backdrop where revenue ranges from ¥29.2b to ¥39.0b and EPS moves between ¥385.45 and ¥536.89. Across recent quarters, the company has seen revenue fluctuate between ¥7.0b and ¥11.1b while basic EPS has shifted from ¥45.00 to ¥216.43. This gives investors a clearer view of how the top line and per-share results are tracking...

Why Toray’s latest moves matter for shareholders Toray Industries (TSE:3402) has been in focus after joining a 14 company supply chain for renewable plastics tied to Sony products, alongside fresh nine month earnings and updated full year guidance. For you as a shareholder or potential investor, these three developments line up in an interesting way. You have a new role for Toray in a global materials project, a snapshot of recent profitability, and management’s current view of the year ahead...

Hodogaya Chemical (TSE:4112) has put its latest numbers on the table, with Q2 2026 revenue at ¥11.2b and basic EPS of ¥38.92, alongside net income of ¥619m. This gives investors fresh data on how the business is running ahead of its Q3 2026 update. The company has seen revenue move between ¥10.6b and ¥14.5b over the last six reported quarters, while basic EPS ranged from ¥18.56 to ¥107.52. This outlines a wide band of earnings outcomes that frames how you might read the latest print and what...

OVAL (TSE:7727) has put fresh numbers on the table for Q3 2026, with Q2 2026 revenue at ¥3,704 million and basic EPS of ¥11.19, alongside trailing 12 month EPS growth of 23.9% and a 5 year annualised earnings growth rate of 40.7%. The company has seen revenue move from ¥3,299 million in Q1 2025 to ¥3,829 million in Q2 2025, then to ¥3,574 million in Q3 2025 and ¥4,346 million in Q4 2025. Over the same period, quarterly basic EPS ranged between ¥6.25 and ¥15.71, setting up a picture where...

Kuriyama Holdings (TSE:3355) has put another quarter on the books, with FY 2025 Q3 revenue at ¥22.8b and basic EPS of ¥49.67, set against a trailing twelve month EPS of ¥223.83 on revenue of ¥85.1b. The company has seen revenue move from ¥19.0b in FY 2024 Q4 to ¥22.8b in FY 2025 Q3, while quarterly EPS shifted from ¥39.99 to ¥49.67 over the same stretch. This gives investors a clearer view of how recent trading is feeding through to the bottom line. With a trailing net profit margin of 5.2%...

STI Foods HoldingsInc (TSE:2932) has just posted its FY 2025 third quarter numbers, with revenue of ¥10.1b and basic EPS of ¥24.52, while trailing twelve month EPS stands at ¥114.58 on revenue of ¥37.7b. The company has seen revenue move from ¥34.7b to ¥37.7b and trailing EPS shift from ¥109.80 to ¥114.58 over the last reported twelve month periods, giving you a clear read on how the top line and per share earnings have tracked together. With trailing net profit margin edging from 5.6% to...

oRo (TSE:3983) has put fresh numbers on the table for FY 2025, reporting third quarter revenue of ¥2.1 billion and basic EPS of ¥30.64. This is set against a trailing 12 month net profit margin of 23.8% compared with 24.1% in the prior year. The company has seen quarterly revenue move between ¥1.9 billion and ¥2.1 billion over the past few periods, while basic EPS has ranged from ¥21.69 to ¥42.90. This gives investors a clear view of how earnings track alongside that high margin profile. See...

Dainichiseika Color & Chemicals Mfg (TSE:4116) has laid out its latest Q3 2026 scorecard with recent quarterly revenue figures running around ¥30.0b and Basic EPS in the double to triple digit yen range, set against trailing 12 month EPS between roughly ¥351 and ¥656 and revenue between about ¥122.4b and ¥125.1b over the past five reported quarters. The company has seen revenue move in a relatively tight band of roughly ¥30.0b to ¥32.2b per quarter and EPS swing from about ¥8 to almost ¥379...

Takeda Pharmaceutical received FDA priority review for its orexin agonist for narcolepsy type 1, marking an important regulatory milestone for the therapy. The company also announced a multi year AI drug discovery collaboration with Iambic, focused on oncology and gastrointestinal candidates. Both developments arrive as Takeda Pharmaceutical (TSE:4502) trades at ¥5,614.0 per share. Takeda Pharmaceutical (TSE:4502) enters these announcements with a share price of ¥5,614.0 and multi year...

Mimaki Engineering (TSE:6638) has just posted its latest numbers, with Q2 2026 revenue at ¥19.97b and basic EPS of ¥49.50, alongside net income of ¥1,432m. The company has seen revenue move from ¥20.43b in Q3 2025 to ¥19.97b in Q2 2026, while quarterly basic EPS has ranged from ¥61.30 in Q2 2025 to ¥41.91 in Q4 2025 and then ¥49.50 in the most recent quarter, framing a results season where margins are very much in focus for investors. See our full analysis for Mimaki Engineering. With the...

Fukuda (TSE:1899) has put solid numbers on the table for FY 2025 so far, reporting third quarter revenue of ¥42,230 million and basic EPS of ¥229.11. These figures are supported by trailing 12 month revenue of about ¥169.7 billion and EPS of ¥702.19. The company has reported revenue ranging from ¥34,299 million in FY 2024 Q2 to ¥49,987 million in FY 2024 Q4. Over the same periods, basic EPS has moved from ¥69.74 to ¥229.11, giving investors a clearer view of how the top and bottom lines have...

Fujii Sangyo (TSE:9906) has put up another solid set of numbers, with Q2 2026 revenue of ¥26.8 billion and basic EPS of ¥170.78, while trailing twelve month revenue sits at ¥101.9 billion and EPS at ¥579.82, alongside net earnings growth of 35.3% over the last year. Over the past few quarters the company has seen revenue move from ¥24.7 billion and EPS of ¥81.58 in Q3 2025 to ¥26.8 billion and EPS of ¥170.78 in Q2 2026, against a backdrop of trailing net profit margin improving to 4.8% from...